View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 21, 2022

Bristol-Myers Squibb’s Abecma gets approval in Japan for multiple myeloma

The approval for Abecma is based on data obtained from the Phase II Study BB2121-MM-001 and the Phase I Study CRB-401.

Bristol-Myers Squibb has received approval from Japan’s Ministry of Health, Labour and Welfare for its therapy Abecma (idecabtagene vicleucel) to treat relapsed or refractory (R/R) multiple myeloma in adults, according to an announcement.

Abecma is a chimeric antigen receptor (CAR) T cell immunotherapy directed by B-cell maturation antigen (BCMA).

In March last year, the company’s CD19-directed genetically modified autologous T cell immunotherapy Breyanzi received approval.

With the latest approval, Bristol Myers Squibb now has two approved CAR T cell therapies.

The Ministry’s approval is based on safety and efficacy data obtained from the international Phase II Study BB2121-MM-001 and the Phase I Study CRB-401 conducted in the US.

The Phase II study was conducted in Japan, the EU, the US and Canada.

Bristol-Myers Squibb president and CEO Jean-Christophe Barland said: “Abecma delivers a new treatment option for patients with multiple myeloma, the first option directed against BCMA and using a new mode of action.

“This approval is a testament to our strong commitment to addressing unmet medical needs for patients in Japan. As a game-changer committed to ‘innovation with heart,’ Bristol Myers Squibb Japan will continue its efforts to help patients prevail over serious diseases.”

The personalised immune cell therapy Abecma, which received approval as a one-time infusion, identifies and attaches to the BCMA protein as an anti-BCMA CAR T cell therapy.

BCMA is universally expressed on multiple myeloma cancer cells and results in their death.

Till now, multiple myeloma has no approved therapeutic options in Japan.

Last August, the European Commission granted conditional marketing authorisation to Bristol Myers Squibb’s Abecma to treat relapsed and refractory multiple myeloma in adult patients.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy